Cognoptix Drug/Device Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in a 10-Subject Proof-of-Concept Clinical Trial
1/3/2013 9:36:40 AM
ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company announced today that its SAPPHIRE II eye test identified Alzheimer’s disease patients via a beta amyloid (“Ab”) signature in their eyes in a 10-subject proof-of-concept clinical trial. By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer’s disease.
comments powered by